Answers are grounded in this paper and cite their sources.
Review reveals advances and obstacles in targeted nanocarriers for myocardial infarction, indicating delivery strategies to improve cardiac repair.
Myocardial infarction is a major cause of morbidity and mortality worldwide. Due to poor inherent regeneration of the adult mammalian myocardium and challenges with effective drug delivery, there has been little progress in regenerative therapies. Nanocarriers, including liposomes, nanoparticles, and exosomes, offer many potential advantages for the therapy of myocardial infarction, including improved delivery, retention, and prolonged activity of therapeutics. However, there are many challenges that have prevented the widespread clinical use of these technologies. This review aims to summarize significant principles and developments in the field, with a focus on nanocarriers using ligand-based or cell mimicry-based targeting. Lastly, a discussion of limitations and potential future direction is provided.
No takes yet. Share an insight, caveat, or question.
George et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: